FDA Panel Will Bring A SHARP Eye To Vytorin, Zetia sNDAs For Chronic Kidney Disease

The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Nov. 2 to discuss whether the SHARP study results support use of the cholesterol-lowering agents for cardiovascular risk reduction in patients with renal disease.